Bone targeted treatments in cancer - The story so far.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Opportunistic Osteoporosis Screening in Breast Cancer Using AI-Derived Vertebral BMD from Routine CT: Validation Against QCT and Multivariable Diagnostic Modeling.Journal of clinical medicine · 2026
   Article
2. The osteoblast in regulation of tumor cell dormancy and bone metastasis.Journal of bone oncology · 2024
   Article
3. Interplay between fat cells and immune cells in bone: Impact on malignant progression and therapeutic response.Pharmacology & therapeutics · 2022
   Review
4. Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval.Journal of bone oncology · 2022
   Review
5. Targeting Histone Modifications in Bone and Lung Metastatic Cancers.Current osteoporosis reports · 2021
   Review
6. From Good to Bad: The Opposing Effects of PTHrP on Tumor Growth, Dormancy, and Metastasis Throughout Cancer Progression.Frontiers in oncology · 2021
   Review
7. Bone microenvironment signaling of cancer stem cells as a therapeutic target in metastatic prostate cancer.Cell biology and toxicology · 2020
   Review
8. The Endosteal Niche in Breast Cancer Bone Metastasis.Frontiers in oncology · 2020
   Review
9. Targeting the Metastatic Bone Microenvironment by MicroRNAs.Frontiers in endocrinology · 2018
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as